Clinical Study
Neoadjuvant Chemoradiation in Squamous Cell Carcinoma of the Maxillary Sinus: A 26-Year Experience

Matthias Kreppel,1,2 Sarah Danscheid,1,2 Martin Scheer,1,2 Jan Christoffer Lüers,2,3 Hans Theodor Eich,4 Joachim E. Zöller,1,2 Orlando Guntinas-Lichius,5 and Dirk Beutner2,3

1 Department of Oral and Cranio-Maxillo and Facial Plastic Surgery, University of Cologne, Kerpener Straße 62, 50931 Cologne, Germany
2 Center of Integrated Oncology (CIO) Cologne-Bonn, Kerpener Straße 62, 50931 Cologne, Germany
3 Department of Otorhinolaryngology, Head and Neck Surgery, University of Cologne, Kerpener Straße 62, 50931 Cologne, Germany
4 Department of Radiotherapy and Radiation Oncology, University of Münster, Albert-Schweitzer-Campus 1, 48149 Münster, Germany
5 Department of Otorhinolaryngology, Head and Neck Surgery, Jena University Hospital, Kerpener Straße 62, 50931 Cologne, Germany

Correspondence should be addressed to Matthias Kreppel, mattheskreppel@yahoo.de

Received 15 May 2012; Revised 21 August 2012; Accepted 2 September 2012

Academic Editor: J. B. Vermerken

Copyright © 2012 Matthias Kreppel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. The aim of our study was to evaluate the effects of neoadjuvant platinum-based radiochemotherapy (RCT) in patients with maxillary sinus squamous cell carcinoma and to compare the results with other multimodality treatment concepts for advanced-stage maxillary sinus carcinoma in the literature. Methods. In total, 53 patients with squamous cell carcinoma of the maxillary sinus were reviewed retrospectively. All patients received a neoadjuvant RCT containing either cisplatin or carboplatin followed by radical surgery. Overall survival and locoregional control were plotted by Kaplan-Meier analysis. Prognostic factors were identified through univariate and multivariate analysis. Results. Five-year overall survival for all patients was 35%. Eleven patients achieved a complete response after radiochemotherapy. The complete response rate was significantly higher for patients treated with cisplatin ($P = 0.028$); however the 5-year overall survival rates did not differ significantly ($P = 0.673$) for patients treated with cisplatin (37%) and carboplatin (32%). Orbital invasion ($P = 0.005$) and complete response to radiochemotherapy ($P = 0.021$) had a significant impact on overall survival in univariate analysis. Conclusions. Neoadjuvant radiochemotherapy followed by radical surgery is an effective treatment for patients with advanced maxillary sinus squamous cell carcinoma. In terms of treatment response cisplatin seems to be more effective than carboplatin.

1. Introduction
Carcinomas of the paranasal sinus are rare, representing 0.2–0.8% of all cancer and 3–5% of the malignant tumors in the head and neck region [1]. The annual incidence is 1-2 per 100,000. The maxillary sinus is the most frequent origin of primary paranasal sinus malignancies [2]. Management of patients with paranasal sinus carcinomas remains a great challenge due to several reasons. Most patients present with a locoregionally advanced disease as the tumor remains asymptomatic for a long time and even early symptoms are similar to common nasal complaints [3]. The complexity of the anatomic site and the histologic heterogeneity leads to difficulties in the classification and staging of paranasal sinus carcinoma [4, 5]. Correct staging however is mandatory as otherwise the patients cannot be assigned to the best treatment scheme for their individual situation, and the treatment effects cannot be evaluated properly [6]. This is particularly important for rare tumors such as maxillary sinus carcinomas as no prospective randomized trials have been conducted and no standardized treatment regime has evolved so far [4, 7]. Therefore, the optimal treatment approach for locally advanced paranasal sinus carcinoma remains controversial.
Only few centers have published treatment results of large groups for patients with paranasal sinus carcinoma, all of them carrying the inherent patient selection bias in retrospective studies, leading to a selection of patients with small resectable tumors [8, 9]. Despite improvements in surgery and radiotherapy (RT) during the last years, patients with advanced stage maxillary sinus carcinoma still have a dismal prognosis, yielding 5-year overall survival rates of 35–49% [10, 11]. Study results suggest that surgery should be incorporated into a treatment regime for patients treated with curative intent [12]. A meta-analysis revealed that disease specific survival after five years is significantly higher for patients treated with surgery plus adjuvant radiotherapy (RT) (66%) than for patients treated with RT alone (46%) [4]. Today, a multimodal treatment regime consisting of surgery, RT, and chemotherapy (CT) is generally applied for patients with advanced-stage head and neck cancers [13, 14]. Several studies have demonstrated that addition of platinum-based CT to adjuvant RT may be beneficial for patients with advanced head neck cancer [15, 16]. The rationale to incorporate CT into multimodal treatment schemes is the synergistic effects with RT, which are the increased tumor cell death through inhibition of the DNA repair in tumor cells, the decrease in tumor mass, the subsequent reoxygenation and radioing of hypoxic tumor cells, and the selective toxicity depending on the cell cycle phase and induction of apoptosis [17]. Concomitant radiochemotherapy (RCT) seems to be more effective than sequential strategies resulting in a survival gain of 6.5% at 5 years. Sequential application of RT and CT yielded worse results [18]. However, the incorporation of platinum analogues is associated with higher neurotoxic side effects [19].

The question of when RCT should be administered—preoperatively or postoperatively—remains open. Several studies have proven the effect and security of neoadjuvant RCT followed by radical surgery for advanced-stage oral squamous cell carcinoma [20–24]. We could demonstrate recently that neoadjuvant RCT is superior to primary surgery followed by adjuvant RCT in patients with oral squamous cell carcinoma with cervical lymph node involvement of stage N2 [25]. Preoperative radiochemotherapy reduces the risk of perioperative tumor cell spreading with implanted metastases, facilitates complete resection, and offers the opportunity of tissue preservation and retained functional integrity [26]. The radiotherapeutic effect is improved in comparison to postoperative radiochemotherapy, due to a higher oxygenation of the tumor [17]. However, this treatment approach can be associated with a higher rate of peri- and postoperative complications [17]. Most centers however advocate primary surgery followed by adjuvant RT or RCT [27]. The major advantages of this concept are the opportunity to obtain a histopathological staging (pTNM) and fewer peri- and postoperative complications.

Neoadjuvant treatment of advanced-stage head and neck cancer has a long tradition at the University of Cologne. Knöbber et al. published promising results on preoperative radiotherapy for patients with oral and oropharyngeal cancer treated at our institutions between 1973 and 1984 [28]. In 1994 results for concomitant cisplatin-based neoadjuvant RCT followed by radical surgery for advanced-stage oral squamous cell carcinoma were published [29].

The aim of the present study was to evaluate the effects of neoadjuvant platinum-based RCT in patients with maxillary sinus squamous cell carcinomas in two treatment centers and to compare the results with other multimodality treatment concepts for advanced stage maxillary sinus carcinoma in the literature.

2. Material and Methods

2.1. Patients. The retrospective study included 53 treatment-naive patients with biopsy-proven primary squamous cell carcinomas of the maxillary sinus, who were treated with curative intent at the Department of Oral and Maxillofacial Plastic Surgery, University of Cologne and at the Department of Otorhinolaryngology and Head Neck Surgery, University of Cologne, between 1980 and 2006.

In total, there were 187 patients with squamous cell carcinoma of the maxillary sinus, who presented between 1980 and 2006. Distribution of stages was as follows: Stage I: 20 patients, stage II: 18 patients, stage III: 23 patients, stage IVa: 99 patients, stage IVb: 29 patients, and stage IVc: 8 patients.

As this is a retrospective study, an interdisciplinary team of surgeons and radiation oncologists determined the indications for concurrent postoperative RCT individually so that there are patients with stage II, who were chosen for a neoadjuvant treatment, whereas other patients with more advanced stage tumors were not given a neoadjuvant treatment. The patients’ clinical characteristics are listed in Table 1. For all patients, clinical and pathologic staging was retrospectively updated to the 7th edition of the UICC for carcinomas of the maxillary sinus [30]. Clinical staging was updated from endoscopy of the upper aerodigestive tract and radiological diagnostic procedures such as CT, MRI, conventional tomography, and sonographic and scintigraphic pretreatment reports. The clinical size of the lymph nodes was determined by B-scan sonography. Lymph nodes of a diameter >1.5 cm were considered as positive [25]. Patients with distant metastases were excluded from our study.

Clinicopathologic parameters were obtained from the medical charts including the histopathologic and surgical reports. Follow-up data were gathered from a combination of chart reviews and the local government office for registration of residents.

2.2. Treatment. All patients received a concomitant neoadjuvant radiochemotherapy followed by radical surgery. Radiotherapy was delivered by 5–6 MV photons delivered by a linac accelerator in daily fractions of 1.8 Gy five times a week, adding up to a total dose of 39.6 Gy or 50.4 Gy to the primary tumor and to the neck lymph node levels I-V by opposing lateral ports. Supraclavicular nodes were treated in an anterior-posterior field. Carboplatin and cisplatin were administered during the first week of radiotherapy for 5 days as a short-term infusion 1 hour before radiation at a dose of 70 mg/m²/day for carboplatin and 40 mg/m²/day for cisplatin. Clinical lymph node status of the neck was assessed
Table 1: Patient and tumor characteristics.

| Patients | 53 |
|----------|----|
| Age (years) |  |
| Mean ± standard deviation | 57.9 ± 11.3 |
| Median | 58.0 |
| Minimum/maximum | 18/78 |
| Gender n (%) |  |
| Male | 41 (77.4%) |
| Female | 12 (22.6%) |
| cT-classification n (%) |  |
| T2 | 3 (5.7%) |
| T3 | 11 (20.8%) |
| T4a | 34 (64.1%) |
| T4b | 5 (9.4%) |
| cN-classification n (%) |  |
| N0 | 28 (52.8%) |
| N1 | 6 (11.3%) |
| N2 | 19 (35.8%) |
| UICC stage grouping n (%) |  |
| II | 2 (3.8%) |
| III | 10 (18.9%) |
| IVa | 36 (67.9%) |
| IVb | 5 (9.4%) |
| Complete response (CR) n (%) |  |
| No | 42 (79.2%) |
| Yes | 11 (20.8%) |
| Orbital infiltration n (%) |  |
| No | 11 (20.8%) |
| Yes | 42 (79.2%) |
| Relapse n (%) |  |
| No | 35 (66.0%) |
| Yes | 18 (34.0%) |
| Radiotherapy n (%) |  |
| 40 Gy | 18 (34.0%) |
| 50 Gy | 35 (66.0%) |
| Chemotherapy n (%) |  |
| Carboplatin | 20 (37.7%) |
| Cisplatin | 33 (62.3%) |

by B-scan sonography, MRI scan, and computer tomography, respectively.

Three to four weeks after the end of the neoadjuvant RCT, all patients received a radical modified neck dissection and a radical resection of the primary tumor, either via lateral rhinotomy or the midfacial degloving approach. Three patients, who refused surgery and therefore did not complete the treatment regime, were excluded from our study. A complete response (CR) was defined by histopathology if no viable tumor cells were detectable in the primary tumor as well as in the neck dissection specimen.

2.3. Statistical Analysis. Structural differences between groups were assessed using the Wilcoxon rank-sum test for continuously distributed variables and the \( \chi^2 \) test and Fisher’s exact test for categorical variables. The Kaplan-Meier survival analysis method was used to estimate the events of interest for overall survival (OS) and locoregional control (LRC). OS was defined as the time interval from beginning of primary therapy until the patient’s death. Patients who did not die were censored at their last date of followup. LRC was defined as the time interval from beginning of primary therapy until locoregional relapse. Patients who did not suffer a locoregional relapse were censored at their last date of follow up [31]. The logrank test was used to compare survival times among patients with different characteristics. \( P \) values of less than 0.05 were considered as significant and printed in bold. A Cox proportional hazard model with forward selection was calculated for multivariate analysis to estimate the impact of prognostic factors in multivariate analysis [32].

3. Results

Table 1 shows the patient and tumor characteristics. At the time of analysis 38 patients were deceased (72%) and 15 were alive. The average and median follow-up times for the patients alive were 98 months and 79 months, respectively. No treatment-related deaths or any cases where patients had to stop the treatment due to toxicity were seen. Radiation in combination with carboplatin was very well tolerated in terms of toxicity and side effects by our patients. 18 patients (34%) suffered a relapse during the followup.

Table 2 displays the results of the univariate analysis. Orbital invasion of the tumor \( (P = 0.005) \) had a significant impact on overall survival \( (P = 0.005) \) and on locoregional control (LRC) \( (P < 0.001) \). As shown in Figure 1, the patients who achieved a CR had a significantly higher 5-year overall survival rate than patients without CR (70% versus 26%,
Table 2: Univariate analysis of prognostic factors.

| Variable                          | 5-year OS | P value | 5-year LRC | P value |
|-----------------------------------|-----------|---------|------------|---------|
| All patients                      | 35.0%     | 0.089   | 58.6%      | 0.627   |
| Age                               |           |         |            |         |
| ≤58 years (lower half of median)  | 43.9%     | 0.627   | 63.9%      |         |
| >58 years (upper half of median)  | 26.9%     | 0.627   | 52.1%      |         |
| Gender                            |           | 0.178   | 0.951      |         |
| Male                              | 30.3%     | 0.627   | 60.1%      |         |
| Female                            | 50.0%     | 0.627   | 56.3%      |         |
| cT-classification                 | 0.497     | 0.135   |            |         |
| T2                                | 33.3%     | 0.135   |            |         |
| T3                                | 30.3%     | 0.135   |            |         |
| T4a                               | 39.1%     | 0.135   |            |         |
| T4b                               | 20.0%     | 0.135   |            |         |
| cN-classification                 | 0.834     | 0.235   |            |         |
| N0                                | 37.2%     | 0.235   | 64.0%      |         |
| N1                                | 53.3%     | 0.235   | 100%       |         |
| N2                                | 28.1%     | 0.235   | 45.3%      |         |
| UICC stage grouping               | 0.228     | 0.191   |            |         |
| II                                | 50.0%     | 0.191   | 100%       |         |
| III                               | 22.5%     | 0.191   | 64.3%      |         |
| IVa                               | 39.7%     | 0.191   | 59.0%      |         |
| IVb                               | 20.0%     | 0.191   | 25.0%      |         |
| Complete response (CR)            | 0.021     | 0.136   | 0.028      |         |
| No                                | 26.0%     | 0.136   | 52.0%      |         |
| Yes                               | 70.0%     | 0.136   | 78.8%      |         |
| Orbital infiltration              | 0.005     | <0.001  | 0.005      |         |
| No                                | 44.0%     | <0.001  | 23.3%      |         |
| Yes                               | 0%        | <0.001  | 68.2%      |         |
| Radiotherapy                      | 0.501     | 0.950   | 0.157      |         |
| 40 Gy                             | 41.7%     | 0.950   | 58.9%      |         |
| 50 Gy                             | 31.3%     | 0.950   | 57.8%      |         |
| Chemotherapy                      | 0.673     | 0.409   | 0.028      |         |
| Carboplatin                       | 31.7%     | 0.409   | 49.4%      |         |
| Cisplatin                         | 37.2%     | 0.409   | 63.9%      |         |

Patients who received cisplatin had a higher 5-year overall survival rate than patients who were treated with carboplatin (37.2% versus 31.7%); however, the differences observed were not statistically significant (P = 0.673). No significant survival differences were observed between the group which received a radiation of 40 Gy and the other group, which received 50 Gy (P = 0.501). Clinical staging criteria did not significantly influence overall survival and locoregional control.

The χ² test revealed that patients who received cisplatin instead of carboplatin had a significantly higher complete response rate after neoadjuvant RCT (P = 0.021). Patients who received cisplatin had a higher 5-year overall survival rate than patients who were treated with carboplatin (37.2% versus 31.7%); however, the differences observed were not statistically significant (P = 0.673). No significant survival differences were observed between the group which received a radiation of 40 Gy and the other group, which received 50 Gy (P = 0.501). Clinical staging criteria did not significantly influence overall survival and locoregional control.

4. Discussion

The main goals in treating paranasal sinus cancer are to cure the cancer, preserve or restore the facial contour and function, minimize the sequelae of treatment, and prevent secondary tumors. However, in patients with advanced tumors...
Numerous studies have shown that a combined modality treatment is required for tumors beyond stage II [33–37]. Sole surgical treatment of advanced tumors leads to a significantly reduced overall survival and locoregional control whereas definitive RT or RCT rarely results in a complete remission and subsequent cure of the tumor [12, 38]. Apart from that, many patients treated with definitive RT at doses of 65 Gy and more suffer from visual impairment. About 20–30% of the patients develop ipsilateral blindness due to optic neuropathy and 10–20% lose their eyesight bilaterally, which seems to be due chiasm injury [39, 40].

In our study, 18 patients received a radiation dose of 40 Gy and 35 patients received 50 Gy. Isobe et al. used a preoperative median radiation dose of 60 Gy ranging from 26–76 Gy in combination with 5-fluorouracil or peplomycin, resulting in a 5-year overall survival rate of 57% [41]. They concluded that the total dose of the radiation and the cumulative dose of the chemotherapy did not have a significant influence on the outcome. Ashraf et al. used a dose of 50 Gy for patients receiving preoperative radiotherapy for cancer of the maxillary sinus [42]. The 5-year survival rate for these patient subgroups was 47%. But it has to be taken into account that most of the patients had T3 tumors and not T4 tumor like in our study sample. At our institution we applied 40–50 Gy in a preoperative setting for head and neck squamous cell carcinoma. This dose results in a mild toxicity [20, 43] and was developed from the experience of previous studies carried out at our department [28, 29]. However, there are no studies that compare the effects of different radiation doses in a neoadjuvant setting.

However, the “ideal combination” of the different treatment modalities of surgery RT and CT is still under debate. The first study conducted on this matter could not detect any significant differences between preoperative and postoperative irradiation [44].

Only one study could detect a significant difference between pre- and postoperative RT. Hu et al. found a significantly higher 5-year overall survival for patients treated with preoperative RT (64%) than for patients treated with postoperative RT (26%) [45]. However, no CT was administered during treatment. A meta-analysis of all kinds of head and neck cancers reported an increase of overall survival of 4.5% at 5 years for all patients who received CT in addition to RT. For patients who were treated in a concomitant setting the survival gain was even higher (6.5%) [46]. In 2002, Nibu et al. published a study on 25 patients with squamous cell carcinoma of the maxillary antrum treated with neoadjuvant RCT consisting of 30–40 Gy and intraarterial infusion of cisplatin in combination with 5-FU. For eight patients with skull base invasion, the CT was administered intravenously. In this study an excellent 5-year overall survival rate of 72% was achieved [36]. Madison et al. used the RADPLAT protocol to treat patients with advanced paranasal sinus carcinoma. Patients received four intraarterial infusions of cisplatin and 50 Gy in a neoadjuvant concomitant setting [47]. Six weeks after the end of the RCT, a radical surgery was performed via a craniofacial approach. The 5-year overall survival rate was 81%. However, there are some limitations to the study as the total number of patients was only 11 with none of the patients having cervical lymph node metastases. The latter is of importance as cervical lymph node metastases are considered to be one of most adverse prognostic factors [48]. The incidence of cervical lymph node metastases is reported to be 10–20% [40, 49]. In our study, 47% of the patients exhibited cervical lymph node metastases at the time of diagnosis. A possible explanation for this relatively high percentage is that the patients at our institutions treated with neoadjuvant RCT and radical surgery were patients considered to be at a high risk level with an unresectable disease. This might explain the lower overall survival rate of 35% at five years in our treatment group.

Eleven patients (21%) achieved a CR through the neoadjuvant RCT. Some studies that examined neoadjuvant RCT in patients with paranasal sinus carcinoma did not provide any information on the response [36, 45]. Hanna et al. reported a partial response rate of 67% after neoadjuvant induction chemotherapy consisting of a platinum derivate and a taxane or a combination with a third agent, such as ifosfamide or 5-fluorouracil. They found that response to the induction chemotherapy but not the subsequent local therapy (surgery, definitive radiotherapy, or radiochemotherapy) was predictive for overall survival of the patients [50]. Patients who had no histopathological sign of a residual vital tumor after neoadjuvant RCT had a 5-year overall survival rate of 70%. Patients with incomplete response or nonresponse had a significantly lower 5-year overall survival rate of 26%

Table 4: Multivariate analysis of prognostic factors (RR = relative risk; CI = confidence interval).

| Variable                  | Category                        | P value | RR      | 95% CI     |
|---------------------------|---------------------------------|---------|---------|------------|
| Age                       | ≤58 years versus >58 years      | 0.292   | 0.688   | 0.32–1.41  |
| UICC stage grouping       | II and III versus Iva and Ivb   | 0.110   | 0.540   | 0.25–1.15  |
| Complete response         | CR versus no CR                 | 0.157   | 0.463   | 0.16–1.34  |
| Orbital infiltration      | No versus yes                   | 0.012   | 0.348   | 0.15–0.79  |
| Chemotherapy              | Cisplatin versus carboplatin    | 0.957   | 0.979   | 0.46–2.10  |
A major problem in analyzing the treatment results for patients with neoadjuvant RCT is that no pTNM is available. As a consequence, meticulous clinical examinations including imaging techniques such as CT, MRI, PET, and endoscopic exploration of the upper aerodigestive tract are required in order to provide detailed and reliable staging information. Although pathological staging is regarded superior to clinical staging in head neck cancer [54], a recent study demonstrated that the prognostic value of clinical staging is equal to pathologic staging [55].

In our study, patients treated with cisplatin had a significantly higher complete response rate than patients treated with carboplatin \((P = 0.028)\). Out of 11 patients with complete response, 10 patients received cisplatin instead of carboplatin. Cisplatin is generally preferred to carboplatin in most centers and seems to yield higher response rates in various types of squamous cell head and neck cancer [21, 24, 56–58]. Two prospective studies compared the effects of cisplatin and carboplatin. Both studies demonstrated advantages for cisplatin over carboplatin [59, 60]. However, the settings in both studies substantially differed from our study. In the study of the Southwest Oncology Group (SWOG), comprising 277 patients with carcinoma from all different sites of the head and neck, the effects of cisplatin and 5-FU versus carboplatin and 5-FU were compared. Despite a higher response rate in the cisplatin group (32% versus 21%) survival was similar for both groups. However, ototoxicity and renal and hematologic toxic effects were substantially greater in the cisplatin group [60]. The other study found a significantly higher response rate for patients with different head and neck tumors treated with cisplatin in comparison to carboplatin. However, the CT was administered as an induction CT and not concomitant [59]. A prospective randomized trial comparing the effects in a concomitant setting with RT is still missing.

In summary, our study results indicate that neoadjuvant radiochemotherapy followed by radical surgery is an option for patients with locoregionally advanced maxillary sinus squamous cell carcinoma. Patients who achieve a complete response after neoadjuvant RCT have a very good prognosis despite the advanced tumor stage; however, patients who do not respond still have a dismal prognosis. In terms of treatment response, cisplatin seems to be more effective than carboplatin for these tumors.

References

[1] R. L. Carrau, E. M. Myers, and J. T. Johnson, “Paranasal sinus carcinoma—diagnosis, treatment, and prognosis,” Oncology, vol. 6, no. 1, pp. 43–50, 1992.
[2] C. S. Muir and J. Nectoux, “Descriptive epidemiology of malignant neoplasms of nose, nasal cavities, middle ear and accessory sinuses,” Clinical Otolaryngology and Allied Sciences, vol. 5, no. 3, pp. 195–211, 1980.
[3] P. Dulgue, and A. S. Allal, “ Nasal and paranasal sinus carcinoma: how can we continue to make progress?” Current Opinion in Otolaryngology and Head and Neck Surgery, vol. 14, no. 2, pp. 67–72, 2006.
[4] P. Dulgue, M. S. Jacobson, A. S. Allal et al., “ Nasal and paranasal sinus carcinoma: are we making progress?” A series of 220 patients and a systematic review,” Cancer, vol. 92, no. 12, pp. 3012–3029, 2003.
[5] M. Kreppel, M. Scheer, D. Beutner et al., “ Stage grouping on tumours of the ethmoid sinuses and the nasal cavity using the sixth edition of the UIICC classification of malignant tumors,” Head & Neck, vol. 33, pp. 1467–1475, 2011.
[6] F. L. Greene and L. H. Sobin, “The staging of cancer: a retrospective and prospective appraisal,” CA: A Cancer Journal for Clinicians, vol. 58, no. 3, pp. 180–190, 2008.
[7] O. Guntinas-Lichius, M. P. Kreppel, H. Stuetzer, R. Semrau, H. E. Eckel, and R. P. Mueller, “ Single modality and multimodality treatment of nasal and paranasal sinuses cancer: a single institution experience of 229 patients,” European Journal of Surgical Oncology, vol. 33, no. 2, pp. 222–228, 2007.
[8] D. Goldenberg, A. Golz, M. Fradis, D. Márta, A. Netzer, and H. Z. Joachims, “ Malignant tumors of the nose and paranasal sinuses: a retrospective review of 291 cases,” Ear, Nose and Throat Journal, vol. 80, no. 4, pp. 272–277, 2001.
[9] W. R. Panje, A. J. Namon, E. Vokes, D. J. Haraf, and R. R. Weichselbaum, “ How I do it: head and neck and plastic surgery: surgical management of the head and neck cancer patient following concomitant multimodality therapy,” The Laryngoscope, vol. 105, no. 1, pp. 97–101, 1995.
[10] N. Bhattacharyya, “Survival and staging characteristics for non-squamous cell malignancies of the maxillary sinus,” Archives of Otolaryngology—Head & Neck Surgery, vol. 129, no. 3, pp. 334–337, 2003.
[11] G. Grau, M. H. Jakobsen, G. Harbo et al., “Sino-nasal cancer in Denmark 1982–1991: a nationwide survey,” Acta Oncologica, vol. 40, no. 1, pp. 19–23, 2001.
[12] T. S. Katz, W. M. Mendenhall, C. G. Morris, R. J. Amdur, R. W. Hinerman, and D. B. Villaret, “ Malignant tumors of the nasal cavity and paranasal sinuses,” Head and Neck, vol. 24, no. 9, pp. 821–829, 2002.
[13] J. Bernier, C. Domenge, M. Ozsahin et al., “Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer,” The New England Journal of Medicine, vol. 350, no. 19, pp. 1945–1952, 2004.
[14] J. S. Cooper, T. F. Pajak, A. A. Forastiere et al., “Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck,” New England Journal of Medicine, vol. 350, no. 19, pp. 1937–2019, 2004.

[15] D. J. Adelstein, Y. Li, G. L. Adams et al., “An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiation therapy in patients with unresectable squamous cell head and neck cancer,” Journal of Clinical Oncology, vol. 21, no. 1, pp. 92–98, 2003.

[16] J. M. Bachaud, E. Cohen-Jonathan, C. Alzieu, J. M. David, E. Serrano, and N. Daly-Schechter, “Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial,” International Journal of Radiation Oncology Biology Physics, vol. 36, no. 5, pp. 999–1004, 1996.

[17] J. Bernier, “Current state-of-the-art for concurrent chemoradiation,” Seminars in Radiation Oncology, vol. 19, no. 1, pp. 3–10, 2009.

[18] J. P. Pignon, J. Bourhis, C. Domenge, L. Designé, and MACH-NC Collaborative Group, “Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data,” The Lancet, vol. 355, no. 9208, pp. 949–955, 2000.

[19] S. Amptoulach and N. Tsavaris, “Neurotoxicity caused by the treatment with platinum analogues,” Chemotherapy Research and Practice, vol. 2011, Article ID 843019, 5 pages, 2011.

[20] H. T. Eich, M. Löschcke, M. Scheer et al., “Neoadjuvant radiochemotherapy and radical resection for advanced squamous cell carcinoma of the oral cavity: outcome of 134 patients,” Strahlentherapie und Onkologie, vol. 184, no. 1, pp. 23–29, 2008.

[21] K. Freier, M. Engel, K. Lindel et al., “Neoadjuvant concurrent radiochemotherapy followed by surgery in advanced oral squamous cell carcinoma (OSCC): a retrospective analysis of 207 patients,” Oral Oncology, vol. 44, no. 2, pp. 116–123, 2008.

[22] T. Kirita, K. Ohgi, H. Shimooka et al., “Preoperative concurrent chemoradiotherapy plus radical surgery for advanced squamous cell carcinoma of the oral cavity: an analysis of long-term results,” Oral Oncology, vol. 35, no. 6, pp. 597–606, 1999.

[23] C. Klug, D. Berzacy, M. Voracek et al., “Preoperative radiochemotherapy in the treatment of advanced oral cancer: outcome of 276 patients,” Journal of Cranio-Maxillofacial Surgery, vol. 37, no. 6, pp. 344–347, 2009.

[24] G. J. Slotman, C. H. Doolittle, and A. S. Glicksman, “Preoperative combined chemotherapy and radiation therapy plus radical surgery in advanced head and neck cancer. Five-year results with impressive complete response rates and high survival,” Cancer, vol. 69, no. 11, pp. 2736–2743, 1992.

[25] M. Kreppel, H. T. Eich, C. Brüggenolte et al., “Preoperative vs. postoperative radiochemotherapy in patients with N2 squamous cell carcinoma of the oral cavity,” Oral Oncology. In press.

[26] J. Wennerberg, “Pre versus post-operative radiotherapy of resectable squamous cell carcinoma of the head and neck,” Acta Oto-Laryngologica, vol. 115, no. 4, pp. 465–474, 1995.

[27] G. Calais, M. Alfonsi, E. Bardet et al., “Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma,” Journal of the National Cancer Institute, vol. 91, no. 24, pp. 2081–2086, 1999.

[28] D. Knöbber, H. Sack, H. Stützer, and K. G. Rose, “Pre-irradiation and surgery of patients with squamous cell carcinoma of the oral cavity and oropharynx: the results of a 1973–1984 study,” Strahlentherapie und Onkologie, vol. 163, no. 11, pp. 706–713, 1987.

[29] R. P. Müller, S. Staar, M. Samek, and H. D. Pape, “Simultaneous preoperative radiochemotherapy with cisplatin in advanced oral cavity carcinomas: acute response and follow-up,” Recent Results in Cancer Research, vol. 134, pp. 165–172, 1994.

[30] C. Wittekindt and H. J. Meyer, “Head neck cancer,” in UICC’s TNM-Classification of Malignant Tumors, pp. 23–60, Springer, Berlin, Germany, 2010.

[31] E. L. Kaplan and P. Meier, “Non-parametric estimation from incomplete observations,” Journal of the American Statistical Association, vol. 53, no. 282, pp. 457–481, 1958.

[32] D. Cox, “Regression modell and life-tables,” Journal of the Royal Statistical Society B, no. 2, pp. 187–220, 1972.

[33] D. Brasnu, O. Laccourreye, V. Bassot, L. Laccourreye, P. Nau-do, and F. X. Roux, “Cisplatin-based neoadjuvant chemotherapy and combined resection for ethmoid sinus adenocarcinoma reaching and/or invading the skull base,” Archives of Otolaryngology—Head & Neck Surgery, vol. 122, no. 7, pp. 765–768, 1996.

[34] J. A. Kang, S. Cho, J. Pyeong-Kim et al., “Treatment outcomes between concurrent chemoradiotherapy and combination of surgery, radiotherapy, and/or chemotherapy in stage III and IV maxillary sinus cancer: multi-institutional retrospective analysis,” Journal of Oral and Maxillofacial Surgery, vol. 70, no. 7, pp. 1717–1723, 2012.

[35] W. Mann and C. Schuler-Voith, “Tumors of the paranasal sinuses and the nose—a retrospective study in 136 patients,” Rhinology, vol. 21, no. 2, pp. 173–177, 1983.

[36] K. I. Nibu, M. Sugawara, M. Asai et al., “Results of multimodality therapy for squamous cell carcinoma of maxillary sinus,” Cancer, vol. 94, no. 5, pp. 1476–1482, 2002.

[37] S. Sakai, A. Hohki, H. Fuchihata, and Y. Tanaka, “Multidisciplinary treatment of maxillary sinus carcinoma,” Cancer, vol. 52, no. 8, pp. 1360–1364, 1983.

[38] G. Harbo, T. Bundgaard, J. Overgaard et al., “Cancer of the nasal cavity and paranasal sinuses. A clinico-pathological study of 277 patients,” Acta Oncologica, vol. 36, no. 1, pp. 45–50, 1997.

[39] G. L. Jiang, S. L. Tucker, R. Guttenberger et al., “Radiation-induced injury to the visual pathway,” Radiotherapy and Oncology, vol. 30, no. 1, pp. 17–25, 1994.

[40] J. T. Parsons, F. C. Kimsey, W. M. Mendenhall, R. R. Million, N. J. Cassisi, and S. P. Stringer, “Radiation therapy for sinus malignancies,” Otolaryngologic Clinics of North America, vol. 28, no. 6, pp. 1259–1268, 1995.

[41] K. Isobe, T. Uno, T. Hanazawa et al., “Preoperative chemotherapy and radiation therapy for squamous cell carcinoma of the maxillary sinus,” Japanese Journal of Clinical Oncology, vol. 35, no. 11, pp. 633–638, 2005.

[42] M. Ashraf, J. Biswas, A. Dam et al., “Results of treatment of squamous cell carcinoma of the maxillary sinus a 26-year experience,” World Journal of Oncology, vol. 1, no. 1, pp. 28–34, 2010.

[43] A. S. Glicksman, G. J. Slotman, C. H. Doolittle et al., “Concurrent CIS-platinum and radiation with or without surgery for advanced head and neck cancer,” International Journal of Radiation Oncology Biology Physics, vol. 30, no. 5, pp. 1043–1050, 1994.

[44] R. H. Jesse, “Preoperative versus postoperative radiation in the treatment of squamous carcinoma of the paranasal sinuses,” The American Journal of Surgery, vol. 110, no. 4, pp. 552–556, 1965.
[45] Y. Hu, G. Tu, Y. Qi et al., "Comparison of pre- and postoperative radiation in the combined treatment of carcinoma of maxillary sinus," *International Journal of Radiation Oncology Biology Physics*, vol. 8, no. 6, pp. 1045–1049, 1982.

[46] J. P. Pignon, A. L. Maître, E. Maillard, and J. Bourhis, "Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients," *Radiotherapy & Oncology*, vol. 92, no. 1, pp. 4–14, 2009.

[47] M. L. Madison, J. M. Sorenson, S. Samant, and J. H. Robertson, "The treatment of advanced sinonasal malignancies with pre-operative intra-arterial cisplatin and concurrent radiation," *Journal of Neuro-Oncology*, vol. 72, no. 1, pp. 67–75, 2005.

[48] L. L. Myers, B. Nussenbaum, C. R. Bradford, T. N. Teknos, R. M. Esclamado, and G. T. Wolf, "Paranasal sinus malignancies: an 18-year single institution experience," *Laryngoscope*, vol. 112, no. 11, pp. 1964–1969, 2002.

[49] G. E. Kim, E. J. Chung, J. J. Lim et al., "Clinical significance of neck node metastasis in squamous cell carcinoma of the maxillary antrum," *American Journal of Otolaryngology*, vol. 20, no. 6, pp. 383–390, 1999.

[50] E. Y. Hanna, A. D. Cardenas, F. DeMonte et al., "Induction chemotherapy for advanced squamous cell carcinoma of the paranasal sinuses," *Archives of Otolaryngology—Head & Neck Surgery*, vol. 137, no. 1, pp. 78–81, 2011.

[51] V. A. Papadimitrakopoulou, L. E. Ginsberg, A. S. Garden et al., "Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma," *Cancer*, vol. 98, no. 10, pp. 2214–2223, 2003.

[52] M. Lee, E. Vokes, A. Rosen, M. E. Witt, R. R. Weichselbaum, and D. J. Haraf, "Multimodality therapy in advanced paranasal sinus carcinoma: superior long-term results," *The Cancer Journal from Scientific American*, vol. 5, no. 4, pp. 219–223, 1999.

[53] S. Samant, K. T. Robbins, M. Vang, J. Wan, and J. Robertson, "Intra-arterial cisplatin and concomitant radiation therapy followed by surgery for advanced paranasal sinus cancer," *Archives of Otolaryngology—Head & Neck Surgery*, vol. 130, no. 8, pp. 948–955, 2004.

[54] O. Driemel, T. Ettl, O. Kölbl et al., "Outcome and histopathologic regression in oral squamous cell carcinoma after preoperative radiochemotherapy," *Strahlentherapie und Onkologie*, vol. 185, no. 5, pp. 296–302, 2009.

[55] W. M. Koch, J. A. Ridge, A. Forastiere, and J. Manola, "Comparison of clinical and pathological staging in head and neck squamous cell carcinoma—results from Intergroup Study ECOG 4393/RTOG 9614," *Archives of Otolaryngology—Head & Neck Surgery*, vol. 135, no. 9, pp. 851–858, 2009.

[56] K. Fan, C. Lin, C. Kang et al., "Combined-modality treatment for advanced oral tongue squamous cell carcinoma," *International Journal of Radiation Oncology Biology Physics*, vol. 67, no. 2, pp. 453–461, 2007.

[57] K. Soo, E. Tan, J. Wee et al., "Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV non-metastatic squamous cell head and neck cancer: a randomised comparison," *British Journal of Cancer*, vol. 93, no. 3, pp. 279–286, 2005.

[58] C. Mohr, W. Bohndorf, J. Carstens et al., "Preoperative radiochemotherapy and radical surgery in comparison with radical surgery alone. A prospective, multicentric, randomized DOSAK study of advanced squamous cell carcinoma of the oral cavity and the oropharynx (a 3-year follow-up)," *International Journal of Oral and Maxillofacial Surgery*, vol. 23, no. 3, pp. 140–148, 1994.

[59] L. De Andrés, J. Brunet, A. López-Pousa et al., "Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer," *Journal of Clinical Oncology*, vol. 13, no. 6, pp. 1493–1500, 1995.

[60] A. A. Forastiere, B. Metc, D. E. Schuller et al., "Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study," *Journal of Clinical Oncology*, vol. 10, no. 8, pp. 1245–1251, 1992.